Updated 07:15 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,856.50 -0.77% CL 89.08 +0.59% BTC 64,493.46 -1.24%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,857 −0.77% BTC $64,493 −1.24% VIX 19.30 +3.21% latest tape · as of 07:15 UTC
The Screen · Healthcare · Medical Care Facilities

AMN Healthcare Services, Inc. logoAMN Healthcare Services, Inc.

AMN · the NYSE · USD · Market cap $1.8B · 2,664 employees

AMN Healthcare Services, Inc.

FAIL · Does not pass the screen
38.02 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price38.02 USD at the 13 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 13 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 2.64)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $22.51 to $25.89, base estimate $22.51 (screen dated 2026-11-13).

Current read
Distribution ?
Overvalued · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 2.64, read 2026-11-14
  • Ethical does not pass the values gate
Price38.02 USD
Fair value22.51
Ethical score70.0/100
Value readOvervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-12Read Markup37.90+0.3% to today ✓Accumulation gives way to Markup after an 11% rise in 6 weeks
2026-10-02Read Accumulation34.24+11.0% to today ✓Markdown gives way to Accumulation with volume flow in agreement
2026-09-21Read Markdown34.92+8.9% to today Markup gives way to Markdown after a 13% rise in 12 weeks
2026-07-02Read Markup30.80+23.4% to today ✓First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

AMN Healthcare Services, Inc. holds its Distribution at $38.02. Consolidating, no directional conviction, held for 5 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 5 days
Price at the screen$38.02
Valuation17.69 trailing · 50.51 forward price to earnings
Values screenFAIL · score 70.0
Beta0.45
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 38.36% Below 33% Interest-bearing debt is 38.4% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 22.18% Below 49% Money owed to the company is 22.2% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

AMN Healthcare Services,'s business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when AMN's ethical verdict changes

Today AMN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $22.51 fair value estimate, 2.30% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

22.51Conservative22.51Base case25.89Growth case 38.02Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 68.9% above the base estimate.

The Street's Range
28.00Street low 36.00Street average 43.00Street high 38.02Price

Third-party analyst targets: 7 covering, consensus Hold. The average target sits −5% from the screen price.

Reading the gap · Both our model and the Street see limited upside at this price.

Price History & Projections

Where our models see it going: fair-value estimate $22.51, with a range of $22.51 to $25.89, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Nurse staffing surge meets losses and lofty price

Picture a hospital ward short on nurses during the pandemic rush. AMN stepped in with workforce solutions and saw revenue double in a year. Yet the business now trades at 32 times forward earnings while margins sit at minus 1 percent and return on equity is negative. Fair value sits well below the current price and analysts see limited upside from here, so the opportunity rating stays at none.

The ethical screen clears without issue. That single positive does not offset the weak profitability or the stretched valuation after such rapid growth. Healthcare staffing volumes can swing sharply once emergency demand fades, leaving the company exposed to a quick reversal in both top line and cash generation.

High multiples on shrinking or negative earnings often signal the market has yet to price in the downturn. The setup leaves little room for error. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E50.5xexpensive even after accounting for its growth
Trailing P/E17.7xreasonably valued
EPS, trailing2.68
EPS, forward0.94
Revenue growth+2.3%slow but positive growth
Profit margin3.1%barely profitable
Return on equity15.6%a solid return on shareholder capital
FCF yield24.27%
Debt to equity1.05a meaningful debt load worth watching
Current ratio1.13adequate liquidity, worth monitoring
Beta0.45barely tracks the market's swings
Short interest, float0.12%
52-week range14.97 - 49.62
Market cap$1.8B
Employees2,664

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

AMN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Markup · changed $37.90 -20.6% Entry 20

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 20.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 35% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.

2026-11-05 Accumulation $47.74 +5.4% Entry 19

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-04 Accumulation $45.30 -3.8% Entry 18

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Accumulation $47.11 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-02 Accumulation $47.11 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Accumulation $47.11 +0.8% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Accumulation $46.72 +0.0% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Accumulation $46.72 +0.0% Entry 13

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Accumulation $46.72 -0.2% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Accumulation $46.82 +17.1% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 17.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 90% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on AMN

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in AMN's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $30.27 -2.4% · $977 -2.4%
2 months $17.87 +65.4% · $1,654 +65.4%
3 months $19.38 +52.5% · $1,525 +52.5%
6 months $16.27 +81.7% · $1,817 +81.7%
1 year $22.02 +34.2% · $1,342 +34.2%
2 years $52.59 -43.8% · $562 -43.8%
3 years $106.00 -72.1% · $279 -72.1%
5 years $95.73 -69.1% · $309 -69.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever AMN does next, these words stay.

AMN Healthcare Services, Inc. · AMN · Distribution · $38.02
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.